Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022
Sport Associated Dementia
BMJ 372:N168, Stewart, W., 2021
Amyotrophic Lateral Sclerosis
NEJM 377:162-172, Brown, R.H.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Inverse Association between Cancer and Alzheimers Disease: Results from the Framingham Heart Study
BMJ 344:e1442, Driver,J.A.,et al, 2012
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001
Acute Dystonia Induced by Drug Treatment
BMJ 319:623-626, vanHarten,P.N.,et al, 1999
A New Variant of Creutzfeldt-Jakob Disease in the UK
Lancet 347:921-925, 915, 916, 91796., Will,R.G.,et al, 1996
Apolipoprotein E Genotype in Diverse Neurodegenerative Disorders
Ann Neurol 38:131-135, Schneider,J.A.,et al, 1995
The Apolipoprotein E Alleles as Major Susceptibility Factors for Creutzfeldt-Jakob Disease
Lancet 344:1315-1318, 13101994., Amouyel,P.,et al, 1994